AbCellera partners with Vertex to develop multispecific T-cell engagers for autoimmune diseases, other conditions

• AbCellera entered a collaboration with Vertex to discover multispecific T-cell engagers for autoimmune diseases and other conditions.
• AbCellera will lead discovery and early development using its T-cell engager platform; Vertex will fund all R&D costs.
• Vertex secured rights to develop and commercialize therapeutic multispecific antibodies from the collaboration.
• AbCellera will receive USD 28 million upfront; eligible for milestones and tiered royalties on net sales.
• Parties may agree for AbCellera to handle cell line, process development, clinical manufacturing through Phase 1 for selected programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein.